NEW YORK, July 7 (Reuters) - Shares of Amgen Inc (AMGN.O) rose 12.7 percent after the closing bell on Tuesday after its Denosumab drug succeeded in a late-stage study of breast cancer patients. For details, see [ID:nWNAB5078]
Shares were up at $58.88 after closing on the Nasdaq at $52.23.
© Thomson Reuters 2009 All rights reserved.
UK
USuk.reuters.com
Help and Contact Us |
Advertise With Us |
Mobile |
Newsletters |
RSS
|
Interactive TV |
Labs |
Archive |
Site Index |
Video Index
Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers
International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
The Dubai effect